NCT06852807Recruiting
18F-mFBG PET Imaging in the Evaluation of Neuroblastoma
Prospective Clinical Study of 18F-mFBG PET Imaging in Neuroblastoma
Source: ClinicalTrials.gov · Last updated 8 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neuroblastoma.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 4 Feb 2025
- Start date
- 4 Feb 2025
- Primary completion date
- Dec 2027
- Lead sponsor
- First Affiliated Hospital of Zhejiang University
- Diseases
- Neuroblastoma, Childhood cancers
- NCT number
- NCT06852807
What you commit to
- Study type: Observational
- Planned participants: 200
- From 4 Feb 2025 to the primary completion date, Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have received ionizing radiation outside the scope of this experiment for other clinical medical or scientific research purposes within the past year, resulting in an annual radiation exposure dose exceeding 50 mSv.
- Patients who have received experimental drugs or devices (with uncertain efficacy or safety) within one month;
Other illness
- Patients with severe primary diseases such as heart, brain, liver, kidney and hematopoietic system diseases;
- Patients with any condition that the principal investigator of this study deems may cause harm or potential harm in any aspect related to this trial.
Who the study is looking for
- Age 0-18 years old, with legal guardian;
- Clinically suspected or confirmed patients with neuroblastoma;
- If the patient is under 8 years old or unable to write, his/her guardian should understand and comply with the requirements of the study. If the patient is 8 years old or older and has written ability, both the patient and his/her guardian must sign the informed consent.
Age in the registry: - to 18 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Zhejiang University School of Medicine Coordinator of this site? Confirm its status | Hangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.